Beijing Hotgen Biotech Co Ltd Cash Flow-to-Debt Ratio
Beijing Hotgen Biotech Co Ltd cash flow-to-debt ratio. Beijing Hotgen Biotech Co Ltd (688068) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥3.05 Million could theoretically repay 0% of its total liabilities (CN¥278.25 Million) in one year. Check earnings quality score of Beijing Hotgen Biotech Co Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Beijing Hotgen Biotech Co Ltd (2016–2024)
Cash flow-to-debt ratio of Beijing Hotgen Biotech Co Ltd from 2016 to 2024. Historical debt coverage capacity for Beijing Hotgen Biotech Co Ltd across 9 annual periods. Check 688068 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Beijing Hotgen Biotech Co Ltd Cash Flow-to-Debt Ratio by Year (2016–2024)
Beijing Hotgen Biotech Co Ltd cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Beijing Hotgen Biotech Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Beijing Hotgen Biotech Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | CN¥-37.16 Million | CN¥251.77 Million | ▼ -17.8% |
| 2023 | -0.13x | CN¥-25.39 Million | CN¥202.56 Million | ▼ -107.0% |
| 2022 | 1.79x | CN¥978.75 Million | CN¥545.59 Million | ▼ -47.7% |
| 2021 | 3.43x | CN¥2.64 Billion | CN¥771.01 Million | ▲ +224.4% |
| 2020 | 1.06x | CN¥164.62 Million | CN¥155.72 Million | ▲ +316.8% |
| 2019 | 0.25x | CN¥19.37 Million | CN¥76.37 Million | ▼ -73.9% |
| 2018 | 0.97x | CN¥55.04 Million | CN¥56.68 Million | ▲ +18.5% |
| 2017 | 0.82x | CN¥22.95 Million | CN¥28.00 Million | ▼ -47.6% |
| 2016 | 1.56x | CN¥45.54 Million | CN¥29.14 Million | — |